Saffety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study.
Naslov
Saffety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study.
Identifikator
/unibl/sci/idNaucniRad:37280
Tip
Pronađite slične unoseAcademic Article
Datum
Pronađite slične unose2025-08
Bibliografski citat
A. Bar Or, M. Dufek, H. Budincevic, J. Drulovic, M. Habek, L. H Huan, M. SVeber, P. Thomas, FENopta study group S. Grgić, FENopta S. Kidemet Piskac, Saffety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study., THE LANCET NEUROLOGY, Vol. 24, No. 8, pp. 656 - 666, Aug, 2025
Početna stranica
656
Krajnja stranica
666
Je dio
THE LANCET NEUROLOGY
1474-4422
Lista autora
Position: 144685 (17 views)